Journal
NEW ENGLAND JOURNAL OF MEDICINE
Volume 379, Issue 19, Pages 1791-1795Publisher
MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMp1803602
Keywords
-
Categories
Ask authors/readers for more resources
The FDA required labeling changes for the programmed cell death 1 inhibitor pembrolizumab and thalidomide-analogue immunomodulatory agents to include information on increased mortality in multiple myeloma. Yet PD-1 therapy's role in the disease is not a closed book.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
